USRE36268E - Method and apparatus for amperometric diagnostic analysis - Google Patents
Method and apparatus for amperometric diagnostic analysis Download PDFInfo
- Publication number
- USRE36268E USRE36268E US08/679,312 US67931296A USRE36268E US RE36268 E USRE36268 E US RE36268E US 67931296 A US67931296 A US 67931296A US RE36268 E USRE36268 E US RE36268E
- Authority
- US
- United States
- Prior art keywords
- iaddend
- iadd
- blood sample
- cell
- electrodes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 238000004458 analytical method Methods 0.000 title abstract description 5
- 239000012491 analyte Substances 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 210000001124 body fluid Anatomy 0.000 claims abstract description 5
- 239000010839 body fluid Substances 0.000 claims abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 94
- 210000004369 blood Anatomy 0.000 claims description 70
- 239000008280 blood Substances 0.000 claims description 70
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 239000008103 glucose Substances 0.000 claims description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 49
- 235000012000 cholesterol Nutrition 0.000 claims description 46
- 239000003153 chemical reaction reagent Substances 0.000 claims description 43
- 239000007800 oxidant agent Substances 0.000 claims description 27
- 238000007254 oxidation reaction Methods 0.000 claims description 24
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 23
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 229940088598 enzyme Drugs 0.000 claims description 22
- 238000011534 incubation Methods 0.000 claims description 22
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 claims description 21
- 230000001590 oxidative effect Effects 0.000 claims description 21
- 230000003647 oxidation Effects 0.000 claims description 20
- 238000005259 measurement Methods 0.000 claims description 17
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 16
- -1 ferricinium Chemical compound 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- 235000012208 gluconic acid Nutrition 0.000 claims description 9
- 239000000174 gluconic acid Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 108010015776 Glucose oxidase Proteins 0.000 claims description 7
- 102000000019 Sterol Esterase Human genes 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 239000004366 Glucose oxidase Substances 0.000 claims description 6
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 6
- 229940116332 glucose oxidase Drugs 0.000 claims description 6
- 235000019420 glucose oxidase Nutrition 0.000 claims description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 4
- 229930192627 Naphthoquinone Natural products 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 108010055297 Sterol Esterase Proteins 0.000 claims description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 4
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 4
- 150000004056 anthraquinones Chemical class 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 150000002791 naphthoquinones Chemical class 0.000 claims description 4
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 230000007480 spreading Effects 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 150000004057 1,4-benzoquinones Chemical class 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 150000001840 cholesterol esters Chemical class 0.000 claims description 3
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 claims description 2
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 claims description 2
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 claims description 2
- 239000007991 ACES buffer Substances 0.000 claims description 2
- 239000008001 CAPS buffer Substances 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 239000007987 MES buffer Substances 0.000 claims description 2
- 239000007993 MOPS buffer Substances 0.000 claims description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 2
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 2
- 239000007997 Tricine buffer Substances 0.000 claims description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000007998 bicine buffer Substances 0.000 claims description 2
- 229940097217 cardiac glycoside Drugs 0.000 claims description 2
- 239000002368 cardiac glycoside Substances 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 150000004986 phenylenediamines Chemical class 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229930002534 steroid glycoside Natural products 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 239000002759 woven fabric Substances 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000012992 electron transfer agent Substances 0.000 claims 19
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 4
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- CJVYYDCBKKKIPD-UHFFFAOYSA-N 1-n,1-n,2-n,2-n-tetramethylbenzene-1,2-diamine Chemical compound CN(C)C1=CC=CC=C1N(C)C CJVYYDCBKKKIPD-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 description 38
- 238000012360 testing method Methods 0.000 description 26
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 22
- 239000000758 substrate Substances 0.000 description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 239000000370 acceptor Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 9
- 229950006191 gluconic acid Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241000187654 Nocardia Species 0.000 description 6
- 229940058573 b-d glucose Drugs 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 238000004082 amperometric method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 241000186146 Brevibacterium Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 4
- 229960003964 deoxycholic acid Drugs 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000006056 electrooxidation reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003475 lamination Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical group C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000027756 respiratory electron transport chain Effects 0.000 description 3
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 3
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000222480 Schizophyllum Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GTKRFUAGOKINCA-UHFFFAOYSA-M chlorosilver;silver Chemical compound [Ag].[Ag]Cl GTKRFUAGOKINCA-UHFFFAOYSA-M 0.000 description 2
- 238000000970 chrono-amperometry Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001055 reflectance spectroscopy Methods 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- BBCZJRSZHIFFAB-UHFFFAOYSA-N 1-(dimethylamino)-2-hydroxypropane-1-sulfonic acid Chemical compound CC(O)C(N(C)C)S(O)(=O)=O BBCZJRSZHIFFAB-UHFFFAOYSA-N 0.000 description 1
- NOGLQXZIGOQIBD-UHFFFAOYSA-N 1-(dimethylazaniumyl)propane-1-sulfonate Chemical compound CCC(N(C)C)S(O)(=O)=O NOGLQXZIGOQIBD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WOGWYSWDBYCVDY-UHFFFAOYSA-N 2-chlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=CC(=O)C=CC1=O WOGWYSWDBYCVDY-UHFFFAOYSA-N 0.000 description 1
- IGRSQEOIAAGSGS-UHFFFAOYSA-N 2-ethylcyclohexa-2,5-diene-1,4-dione Chemical compound CCC1=CC(=O)C=CC1=O IGRSQEOIAAGSGS-UHFFFAOYSA-N 0.000 description 1
- VTWDKFNVVLAELH-UHFFFAOYSA-N 2-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C=CC1=O VTWDKFNVVLAELH-UHFFFAOYSA-N 0.000 description 1
- QOIXLGYJPBDQSK-UHFFFAOYSA-N 3,6-dioxocyclohexa-1,4-diene-1-sulfonic acid Chemical compound OS(=O)(=O)C1=CC(=O)C=CC1=O QOIXLGYJPBDQSK-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- YQNUXCCHFKYTJR-BTVCFUMJSA-N cyclohexa-2,5-diene-1,4-dione;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound O=C1C=CC(=O)C=C1.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YQNUXCCHFKYTJR-BTVCFUMJSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000005546 reactive sputtering Methods 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/004—Enzyme electrodes mediator-assisted
Definitions
- the present invention relates to a disposable electroanalytical cell and a method and apparatus for quantitatively determining the presence of biologically important compounds such as glucose; TSH; T4; hormones such as HCG; cardiac glycosides such as Digoxin; antiarrhythmics such as Lidocaine; antiepileptics such as phenobarbital; antibiotics such as Gentamicin; cholesterol; non-therapeutic drugs and the like from body fluids.
- biologically important compounds such as glucose; TSH; T4; hormones such as HCG; cardiac glycosides such as Digoxin; antiarrhythmics such as Lidocaine; antiepileptics such as phenobarbital; antibiotics such as Gentamicin; cholesterol; non-therapeutic drugs and the like from body fluids.
- Diabetes and specifically diabetes mellitus, is a metabolic disease characterized by deficient insulin production by the pancreas which results in abnormal levels of blood glucose. Although this disease afflicts only approximately 4% of the population in the United States, it is the third leading cause of death following heart disease and cancer. With proper maintenance of the patient's blood sugar through daily injections of insulin, and strict control of dietary intake, the prognosis for diabetics is excellent. However, the blood glucose levels must be closely followed in the patient either by clinical laboratory analysis or by daily analyses which the patient can conduct using relatively simple, non-technical, methods.
- Dioxygen is the only direct oxidant used with the enzyme cholesterol oxidase for the determination of both free and total cholesterol.
- oxygen must diffuse into the sensor solution during use from the surrounding air in order to provide sufficient reagent for a complete reaction with the analyte cholesterol in undiluted serum and whole blood specimens.
- the presence of the substance is determined by quantifying, either colorometrically or otherwise, the presence of hydrogen peroxide.
- the present methods of detection may include direct measurement of the hydrogen peroxide produced by either spectroscopic or electrochemical means and indirect methods in which the hydrogen peroxide is reacted with various dyes, in the presence of the enzyme peroxidase, to produce a color that is monitored.
- these tests require consistent user technique in order to yield reproducible results. For example, these tests require the removal of blood from a reagent pad at specified and critical time intervals. After the time interval, excess blood must be removed by washing and blotting, or by blotting alone, since the color measurement is taken at the top surface of the reagent pad. Color development is either read immediately or after a specified time interval.
- the present invention addresses the concerns of the physician by providing enzymatic amperometry methods and apparatus for monitoring compounds within whole blood, serum, and other body fluids.
- Enzymatic amperometry provides several advantages for controlling or eliminating operator dependant techniques as well as providing a greater linear dynamic range. A system based on this type of method could address the concerns of the physician hesitant to recommend self-testing for his patients.
- Enzymatic amperometry methods have been applied to the laboratory based measurement of a number of analytes including glucose, blood urea nitrogen, and lactate.
- the electrodes in these systems consist of bulk metal wires, cylinders or disks imbedded in an insulating material. The fabrication process results in individualistic characteristics for each electrode necessitating calibration of each sensor. These electrodes are also too costly for disposable use, necessitating meticulous attention to electrode maintenance for continued reliable use.
- the present invention address these requirements by providing miniaturized disposable electroanalytic sample cells for precise micro-aliquote sampling, a self-contained, automatic means for measuring the electrochemical reduction of the sample, and a method for using the cell and apparatus according to the present invention.
- the disposable cells according to the present invention are preferably laminated layers of metallized plastic and nonconducting material.
- the metallized layers provide the working and reference electrodes, the areas of which are reproducibly defined by the lamination process.
- An opening through these layers is designed to provide the sample-containing area or cell for the precise measurement of the sample. The insertion of the cell into the apparatus according to the present invention, automatically initiates the measurement cycle.
- a presently preferred embodiment of the invention which involves a two-step reaction sequence utilizing a chemical oxidation step using other oxidants than oxygen, and an electro-chemical reduction step suitable for quantifying the reaction production of the first step.
- One advantage to utilizing an oxidant other than dioxygen for the direct determination of an analyte is that they may be prepositioned in the sensor in a large excess of the analyte and thus ensure that the oxidant is not the limiting reagent (with dioxygen, there is normally insufficient oxidant initially present in the sensor solution for a quantitative conversion of the analyte).
- oxidation reaction a sample containing glucose, for example, is converted to gluconic acid and a reduction product of the oxidant.
- This chemical oxidation reaction has been found to precede to completion in the presence of an enzyme, glucose oxidase, which is highly specific for the substrate B-D-glucose, and catalyzes oxidations with single and double electron acceptors. It has been found, however, that the oxidation process does not proceed beyond the formation of gluconic acid, thus making this reaction particularly suited for the electrochemical measurement of glucose.
- oxidations with one electron acceptor using ferricyanide, ferricinium, cobalt (III) . .orthophenantroline.!. .Iadd.orthophenanthroline.Iaddend., and cobalt (III) dipyridyl are preferred.
- Benzoquinone is a two electron acceptor which also provides excellent electro-oxidation characteristics for amperometric quantitation.
- Amperometric determination of glucose for example, in accordance with the present invention utilizes Cottrell current micro-chronoamperometry in which glucose plus an oxidized electron acceptor produces gluconic acid and a reduced acceptor. This determination involves a preceding chemical oxidation step catalyzed by a bi-substrate bi-product enzymatic mechanism as will become apparent throughout this specification.
- the method and apparatus of the . .prevent.!. .Iadd.present .Iaddend.invention permit, in preferred embodiments, direct measurements of blood glucose, cholesterol and the like. Furthermore, the sample cell according to the . .prevent.!. .Iadd.present .Iaddend.invention, provides the testing of controlled volumes of blood without premeasuring. Insertion of the sample cell into the apparatus thus permits automatic functioning and timing of the reaction allowing for patient self-testing with a very high degree of precision and accuracy.
- the sample cell of the invention is used to control the sampling volume and reaction media and acts as the electrochemical sensor.
- benzoquinone is used as the electron acceptor.
- the basic chemical binary reaction utilized by the method according to the present invention is:
- the first reaction is an oxidation reaction which proceeds to completion in the presence of the enzyme glucose oxidase.
- Electrochemical oxidation takes place in the second part of the reaction and provides the means for quantifying the amount of hydroquinone produced in the oxidation reaction. This holds true whether catalytic oxidation is conducted with two-electron acceptors or one electron acceptors such as ferricyanide (wherein the redox couple would be Fe(CN) 6 -3 /Fe(CN) 6 -4 ), ferricinium, cobalt III . .orthophenantroline.!. .Iadd.orthophenanthroline .Iaddend.and cobalt (III) dipyridyl.
- Catalytic oxidation by glucose oxidase is highly specific for B-D-glucose, but is nonselective as to the oxidant. It has now been discovered that the preferred oxidants described above have sufficiently positive potentials to convert substantially all of the B-D-glucose to gluconic acid. Furthermore, this system provides a means by which amounts as small a 1 mg of glucose (in the preferred embodiment) to 1000 mg of glucose can be measured per deciliter of sample--results which have not previously been obtained using other glucose self-testing systems.
- the sensors containing the chemistry to perform the desired determination are used with a portable meter for self-testing systems.
- the sensor In use the sensor is inserted into the meter which turns the meter on and initiates a wait for the application of the sample.
- the meter recognizes sample application by the sudden charging current flow that occurs when the electrodes and the overlaying reagent layer are initially wetted by the sample fluid.
- the meter Once the sample application is detected, the meter begins the reaction incubation step (the length of which is chemistry dependent) to allow the enzymatic reaction to reach completion. This period is on the order of 15 to 90 seconds for glucose, with incubation times of 20 to 45 seconds preferred.
- the instrument then imposes a known potential across the electrodes and measures the current at specific time points during the Cottrell current decay.
- Current measurements can be made in the range of 2 to 30 seconds following potential application with measurement times of 10 to 20 seconds preferred. These current values are then used to calculate the analyte concentration which is then displayed. The meter will then wait for either the user to remove the sensor or for a predetermined period before shutting itself down.
- the present invention provides for a measurement system that eliminates several of the critical operator dependant variables that adversely affect the accuracy and reliability and provides for a greater dynamic range than other self-testing systems.
- FIG. 1 is an exploded view of a portable testing apparatus according to the present invention
- FIG. 2 is a plan view of the sampling cell of the present invention.
- FIG. 3 is an exploded view of the sample cell shown in FIG. 2;
- FIG. 4 is an exploded view of another embodiment of a sample cell according to the invention.
- FIG. 5 is a plan view of the cell shown in FIG. 4;
- FIG. 6 is still another embodiment of a sample cell
- FIG. 7 is a graph showing current as a function of glucose concentration
- FIG. 8 is a graphical presentation of Cottrell current as a function of glucose concentration.
- FIG. 9 is a presently preferred circuit diagram of an electrical circuit for use in the apparatus shown in FIG. 1.
- FIG. 10 is a preferred embodiment of the electrochemical cell.
- a portable electrochemical testing apparatus 10 for use in patient self-testing, such as, for example, for blood glucose levels.
- Apparatus 10 comprises a front and back housing 11 and 12, respectively, a front panel 13 and a circuit board 15.
- Front panel 13 includes graphic display panels 16 for providing information and instructions to the patient, and direct read-out of the test results.
- a start button 18 is provided to initiate an analysis, it is preferred that the system being operation when a sample cell 20 (FIG. 2) is inserted into the window 19 of the apparatus.
- sample cell 20 is a metallized plastic substrate having a specifically-sized opening 21 which defines a volumetric well 21, when the cell is assembled, for containing a reagent pad and the blood to be analyzed.
- Cell 20 comprises a first substrate 22 and a second substrate 23 which may be preferably made from styrene or other substantially non-conducting plastic.
- reference electrode 24 Positioned on second substrate 23 is reference electrode 24.
- Reference electrode 24 may be preferably manufactured, for example, by vapor depositing the electrode onto a substrate made from a material such as the polyimide Kapton.
- reference electrode 24 is a silver-silver chloride electrode. This electrode can be produced by . .first.!.
- the silver chloride layer may even be generated in-situ on a silver electrode when the reagent layer contains certain of the oxidants, such as ferricyanide, and chloride as shown in the following reactions:
- the silver-silver chloride electrode can be produced by depositing a layer of silver oxide (by reactive sputtering) onto the silver film. The silver oxide layer is then converted in-situ at the time of testing to silver chloride according to the reaction:
- the silver electrode is thus coated with a layer containing silver chloride.
- the reference electrode may also be of the type generally known as a "pseudo" reference electrode which relies upon the large excess of the oxidizing species to establish a known potential at a noble metal electrode.
- a noble metal electrode In a preferred embodiment, two electrodes of the same noble metal are used, however one is generally of greater surface area and is used as the reference electrode. The large excess of the oxidized species and the larger surface area of the reference resists a shift of the potential of the reference electrode.
- Indicator or working electrode 26 can be either a strip of platinum, gold, or palladium metallized plastic positioned on reference electrode 24 or alternately the working electrode 26 and the reference electrode may be manufactured as a coplanar unit with electrode 26 being sandwiched between coplanar electrode 24 material.
- sample cell 20 is prepared by sandwiching or laminating the electrodes between the substrate to form a composite unit.
- first substrate 22 is of a slightly shorter length so as to expose an end portion 27 of electrodes 24 and 26 and allow for electrical contact with the testing circuit contained in the apparatus.
- cell 20 is pushed into window 19 of the front panel to initiate testing.
- a reagent may be applied to well 21, or, preferably, a pad of dry reagent is positioned therein and a sample (drop) of blood is placed into the well 21 containing the reagent.
- sample cell 120 is shown having first 122 and second 123 substrates.
- Reference electrode 124 and working electrode 126 are laminated between substrates 122 and 123. Opening 121 is dimensioned to contain the sample for testing.
- End 130 (FIG. 5) is designed to be inserted into the apparatus, and electrical contact is made with the respective electrodes through cut-outs 131 and 132 on the cell.
- Reference electrode 124 also includes cut out 133 to permit electrical contact with working electrode 126.
- working electrode 226 is folded, thereby providing increased surface area around opening 221, to achieve increased sensitivity or specificity.
- reference electrode 224 is positioned beneath working electrode 226.
- Working electrode includes cut out 234 to permit electrical contact with reference electrode 224 through cut out 231 in substrate 222.
- End 230 of substrate 222 also includes cut out 232 to permit electrical contact with working electrode 226.
- the sample cell according to the present invention is positioned through window 19 (FIG. 1) to initiate the testing procedure.
- a potential is applied at portion 27 (FIG. 2) of the sample cell across electrodes 24 and 26 to detect the presence of the sample.
- the potential is removed and the incubation period initiated.
- a vibrator means 31 may be activated to provide agitation of the reagents in order to enhance dissolution (an incubation period of 20 to 45 seconds is conveniently used for the determination of glucose and no vibration is normally required).
- An electrical potential is next applied at portion 27 of the sample cell to electrodes 24 and 26 and the current through the sample is measured and displayed on display 16.
- the needed chemistry for the sell testing systems is incorporated into a dry reagent layer that is positioned onto the disposable cell creating a complete sensor for the intended analyte.
- the disposable electrochemical cell is constructed by the lamination of metallized plastics and nonconducting materials in such a way that there is a precisely defined working electrode area.
- the reagent layer is either directly coated onto the cell or preferably incorporated (coated) into a supporting matrix such as filter paper, membrane filter, woven fabric or non-woven fabric, which is then placed into the cell. When a supporting matrix is used, it pore size and void volume can be adjusted to provide the desired precision and mechanical support.
- the coating formulation generally includes a binder such as gelatin, carrageenan, methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc., that acts to delay the dissolution of the reagents until the reagent layer has adsorbed most of the fluid from the sample.
- concentration of the binder is generally on the order of 0.1 to 10% with 1-4% preferred.
- the reagent layer imbibes a fixed amount of the sample fluid when it is applied to the surface of the layer thus eliminating any need for premeasurement of sample volume. Furthermore, by virtue of measuring current flow rather than reflected light, there is no need to remove the blood from the surface of the reagent layer prior to measurement as there is with reflectance spectroscopy systems. While the fluid sample could be applied directly to the surface of the reagent layer, to facilitate spread of blood across the entire surface of the reagent layer the sensor preferably includes a dispersing spreading or wicking layer. This layer, generally a non-woven fabric or adsorbant paper, is positioned over the reagent layer and acts to rapidly distribute the blood over the reagent layer. In some applications this dispersing layer could incorporate additional reagents.
- the reagent layer was then cut into strips that just fit the window opening of the cells and these strips were place over the electrodes exposed within the windows.
- a wicking layer of a non-woven rayon fabric was then placed over this reagent layer and held in place with an overlay tape.
- Cottrell current (i t ) microchronoamperometry Determination of glucose by Cottrell current (i t ) microchronoamperometry with the present method is created in the reaction of hydroquinone to benzoquinone. Cottrell currents decay with time in accordance with the equation:
- the main difference between these two techniques consists of applying the appropriate controlled potential after the glucose-benzoquinone reaction is complete and correlating glucose concentrations with Cottrell currents measured at a fixed time thereafter.
- the current-time readout is shown in FIG. 8.
- Circuit 15 includes a microprocessor and LCD panel 16.
- the working and reference electrodes on the sample cell 20 make contact at contacts W (working electrode) and R (reference electrode), respectively.
- Voltage reference 41 is connected to battery 42 through analogue power switch 43.
- Current from the electrodes W and R is converted to a voltage by op amp 45. That voltage is converted into a digital signal (frequency) by and voltage to frequency converter 46 electrically connected to the microprocessor 48.
- the microprocessor 48 controls the timing of the signals. Measurement of current flow is converted by microprocessor 48 to equivalent glucose, cholesterol or other substance concentrations.
- Other circuits within the skills of a practiced engineer can obviously be utilized to obtain the advantages of the present invention.
- cell 400 consists of coplanar working 426 and reference 424 electrodes laminated between an upper 422 and lower 423 nonconducting material. Lamination is on an adhesive layer 425.
- the upper material 422 includes a die cut opening 428 which, along with the width of the working electrode material defines the working electrode area and provides (with an overlapping reagent layer not depicted) the sampling port of the cell.
- At one end of cell 400 is an open area 427 similar to end position 27 of FIG. 2.
- the generalized chemistry may be depicted as: ##STR1## where the enzymes cholesterol esterase (CE) and cholesterol oxidase (CO) catalyze reactions 1 and 2 respectively and CO permits electron transfer with a variety of electroactive couples (Ox and Red).
- Reaction 2 is novel in that electron acceptors other than dioxygen may be used to oxidize cholesterol in the presence of the enzyme cholesterol oxidase.
- Reaction 1 is well known to those in the field and is necessary for the determination of total cholesterol (free cholesterol and cholesterol esters).
- Reaction 3 is an electro-oxidation process for probing and quantitating the cholesterol.
- Cholesterol oxidase (CO) from a variety of sources will catalyze electron transfer from cholesterol to a variety of the oxidants including benzoquinone, benzoquinone derivatives such as methylbenzoquinone, ethylbenzoquinone, chlorobenzoquinone, ortho-benzoquinone (oxidized form of catechol), benzoquinonesulfonate, and potassium ferricyanide. It is also anticipated that the enzyme will allow electron transfer with other alternate oxidants. As indicated in Reaction 3, the reduced product can then be monitored amperometrically for the quantitative determination of cholesterol.
- Sources of the enzyme catalyzing the oxidation of cholesterol with alternate oxidants include CO from Nocardia, Streptomyces, Schizophyllum, Pseudomonas, and Brevibacterium; experimental conditions under which it is able to rapidly catalyze the oxidation of cholesterol by benzoquinone or any of the other oxidants depend somewhat upon the source of the enzyme.
- CO from Streptomyces rapidly catalyzes substrate oxidation with benzoquinone in phosphate buffer in the presence of any of a variety of the surfactants including octylgluconopyranoside and CHAPSO; the same reaction under identical conditions with CO from either Brevibacterium or Nocardia is slower.
- both Nocardia and Brevibacterium sources are active catalysts for cholesterol oxidation by alternate oxidants under other conditions.
- the oxidant also plays a role in which the enzyme is most active.
- cholesterol oxidase from Nocardia rapidly catalyzes substrate oxidation with benzoquinone in 0.2 molar TRIS buffer and 3 g/dL CHAPSO but is slower with ferricyanide under identical conditions;
- the Brevibacterium source of the enzyme is relatively inactive with ferricyanide in TRIS buffer with a variety of surfactants but when benzoquinone is used as the oxidant the reaction is very fast.
- the Schizophyllum source of the enzyme CO rapidly catalyzes the oxidation of cholesterol in phosphate buffer with either ferricyanide or benzoquinone and with a variety of surfactants as activators.
- cholesterol oxidase will catalyze the oxidation of cholesterol by ferricyanide.
- Additional examples where CO catalyzes cholesterol oxidation by ferricyanide include a Nocardia source in TRIS buffer with a variety of surfactants including sodium deoxycholate, sodium taurodeoxycholate, CHAPS, Thesit, and CHAPSO.
- CO from Nocardia will also catalyze substrate oxidation with ferricyanide in phosphate buffer with sodium dioctylsulfosuccinate, sodium deoxycholate, sodium taurodeoxycholate, and Triton X-100.
- the buffer concentration is from 0.1 to 0.4 molar.
- Surfactant concentration for maximum activity of the oxidase enzyme varies with each detergent.
- the enzyme in 0.2M TRIS is most active with detergent in the range from 20 to 90 millimolar. However, enzyme catalytic activity is observed up to . .an.!. .Iadd.and .Iaddend.through a 10% concentration. With octyl-gluconopyranoside, the maximum activity of the enzyme with the oxidant ferricyanide occurs at a detergent concentration of approximately 1.2%; however, the enzyme still maintains activity at higher and lower concentrations of the surfactant.
- Both esterase and CO require a surfactant for high activity.
- Specific surfactants include sodium deoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, CHAPS (3-(3-chlolamidopropyl)dimethylammonio-1-propanesulfonate), CHAPSO (3-(3-chlolamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate), octyl-gluconopyranoside, octylthio-gluconopyranoside, nonyl-gluconopyranoside, dodecyl-gluconopyranoside, Triton X-100, Dioctyl sulfosuccinate, Thesit (Hydroxypolyethoxydodecane), and lecithin (phosphatidylcholine).
- Buffers acceptable for this reaction to occur with the enzyme include phosphate, TRIS, MOPS, MES, HEPES, Tricine, Bicine, ACES, CAPS, and TAPS.
- An alternate generallized reaction scheme for the measurement of cholesterol in serum and other biological fluids is given ##STR3## where Ox, and Red 2 function as an electron mediator couple between the cholesterol and the electroactive couple Ox 2 /Red 2 .
- Ox 1 and Red 1 need not be electroactive because they do not have to participate in the electrooxidation process (Reaction 6).
- this couple with the assistance of the enzyme cholesterol oxidase must be able to accept electrons from cholesterol and relay them to the electroactive couple (Ox 2 /Red 2 ).
- Specific examples of this chemistry include
- Scheme II is beneficial when the rate of reaction of cholesterol with the electroactive oxidant as in Scheme I is so slow that it precludes its use in a practical sensor. As mentioned above, Scheme II is also beneficial when the electron mediator itself (Ox 1 /Red 1 ) is either not electroactive or exhibits poor electrochemistry under conditions of the enzyme chemistry. It is under these conditions that Scheme II is particularly applicable.
- Other electron mediators (Ox 1 /Red 1 ) between cholesterol and ferricyanide for use in Scheme II may be possible including phenazine ethosulfate, phenazine methosulfate, tetramethylbenzidine, derivatives of benzoquinone, naphthoquinone and naphthoquinone derivatives, anthraquinone and anthraquinone derivatives, catechol, phenylenediamine, . .tetramethylphenenediamine.!. .Iadd.tetramethylphenylenediamine.Iaddend., and other derivatives of phenylenediamine.
- the oxidized form of the electron relay accepts electrons from cholesterol
- either the oxidized or the reduced form of the mediator may be incorporated provided it reacts rapidly with both cholesterol and ferricyanide.
- reductant may be incorporated into the sensor in relatively small quantity (in comparison with the analyte to be determined) and still provide the electron relay.
- the reductant must also be isolated from ferricyanide in the sensor by incorporation into a separate reagent layer.
- the concentractions provided are . .that.!. .Iadd.those .Iaddend.of the solutions which are coated onto porous supports, filter paper or membranes; . .these.!. .Iadd.those .Iaddend.concentrations are reestablished when the membrane imbibes the serum or whole blood specimen.
- large pore sizes in the filter support are .Iadd.more .Iaddend.necessary than that used for glucose. This is because the cholesterol resides in the serum in large lipoproteins (chylomicrons. ...!. .Iadd., .Iaddend.LDL, VLDL, and HDL) which must penetrate the various layers of the sensor until they reach the reagents.
- the surfactants to the major extent break these natural micelles up into smaller micelles providing a greater total surface . .are.!. .Iadd.area .Iaddend.on which the enzymes catalyze the reaction.
- Due to the instability of benzoquinone.Iadd., .Iaddend. a small quantity of hydroquinone, which is more stable by nature of its lower vapor pressure, is incorporated into the sensor to assist electron mediation between cholesterol and ferricyanide.
- the hydroquinone oxidized to benzoquinone; the benzoquinone is then free to pick up electrons from the substrate and cycle them to ferricyanide. Under these conditions the rate of the reaction of cholesterol with a small quantity of benzoquinone is more rapid than that with a large excess of ferricyanide.
- the magnesium salt in this formulation increases stability of the esterase enzyme in the phosphate-free reagent layer; Lipase assists the break up of the lipoproteins.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
B-D-Glucose+O.sub.2 +H.sub.2 O→D-Gluconic Acid+H.sub.2 O.sub.2
H.sub.2 O.sub.2 +Reagent-H.sub.2 O+color.
Cholesterol+H.sub.2 O+O.sub.2 →Cholestenone+H.sub.2 O.sub.2
H.sub.2 O.sub.2 +Reagent→H.sub.2 O+color.
B-D-glucose+Benzoquinone+H.sub.2 O→Gluconic Acid+Hydroquinone
Hydroquinone→benzoquinone+2e-+2H+.
Ag+Ox→ag.sup.+ +Red
Ag.sup.+ +Cl.sup.- →AgCl.
Ag.sub.2 O+H.sub.2 O+2Cl.sup.- →2AgCl+2(OH).sup.-
______________________________________ Glucose oxidase 600 u/ml Potassium Ferricyanide 0.4M Phosphate Buffer 0.1M Potassium Chloride 0.5M Gelatin 2.0 g/dl ______________________________________
i.sub.r t1/2=const
______________________________________ GLUCOSE SYSTEM COMPARISONS Present Inven-Steps 1 2 3 4 tion ______________________________________ Turn Instrument On X X X X X Calibrate Instrument X X Finger Puncture X X X X X Apply Blood X X X X X Initiate Timing X X X Sequence Blot X X X Insert Strip to Read X X X X Read Results X X X X X Total Steps Per 8 8 7 5 4 Testing Detection System RS* RS RS RS Polaro- graphic Range (mg/dl) 10-400 40-400 25-450 40-400 0-1000 CV**Hypoglycemic 15% 15% 5% Euglycemic 10% 10% 3% Hyperglycemic 5% 5% 2% Correlation 0.921 0.862 0.95 ______________________________________ *RS--Reflectance Spectroscopy **Coefficient of variation
______________________________________ Serum Cholesterol, mg % Average Current, uA ______________________________________ 91 19.3 182 27.2 309 38.5 ______________________________________
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/679,312 USRE36268E (en) | 1988-03-15 | 1996-07-12 | Method and apparatus for amperometric diagnostic analysis |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16829588A | 1988-03-15 | 1988-03-15 | |
US07/322,598 US5128015A (en) | 1988-03-15 | 1989-03-13 | Method and apparatus for amperometric diagnostic analysis |
US07/745,544 US5108564A (en) | 1988-03-15 | 1991-08-15 | Method and apparatus for amperometric diagnostic analysis |
US17686393A | 1993-12-30 | 1993-12-30 | |
US08/679,312 USRE36268E (en) | 1988-03-15 | 1996-07-12 | Method and apparatus for amperometric diagnostic analysis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/745,544 Reissue US5108564A (en) | 1988-03-15 | 1991-08-15 | Method and apparatus for amperometric diagnostic analysis |
US17686393A Continuation | 1988-03-15 | 1993-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE36268E true USRE36268E (en) | 1999-08-17 |
Family
ID=27496781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/679,312 Expired - Lifetime USRE36268E (en) | 1988-03-15 | 1996-07-12 | Method and apparatus for amperometric diagnostic analysis |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE36268E (en) |
Cited By (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010045355A1 (en) * | 2000-03-09 | 2001-11-29 | Clinical Analysis Corporation | Medical diagnostic system |
US6572745B2 (en) | 2001-03-23 | 2003-06-03 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
US6576102B1 (en) | 2001-03-23 | 2003-06-10 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
US20040079652A1 (en) * | 2002-08-27 | 2004-04-29 | Bayer Healthcare Llc | Methods of determining glucose concentration in whole blood samples |
US20040094432A1 (en) * | 2002-04-25 | 2004-05-20 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20040138588A1 (en) * | 2002-11-06 | 2004-07-15 | Saikley Charles R | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US20040182703A1 (en) * | 2002-04-25 | 2004-09-23 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20040253367A1 (en) * | 2003-06-12 | 2004-12-16 | Wogoman Frank W. | Sensor format and construction method for capillary-filled diagnostic sensors |
US20050045476A1 (en) * | 2002-04-25 | 2005-03-03 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20050147811A1 (en) * | 2002-12-17 | 2005-07-07 | Richard Baron | Adhesive articles which contain at least one hydrophilic or hydrophobic layer, method for making and uses for same |
US20050164329A1 (en) * | 2002-05-17 | 2005-07-28 | Wallace-Davis Emma N.K. | Analyte measurement |
US20050194265A1 (en) * | 2004-03-03 | 2005-09-08 | Apex Biotechnology Corp. | Method for reducing measuring bias in amperometric biosensors |
US20060108218A1 (en) * | 2001-03-05 | 2006-05-25 | Clinical Analysis Corporation | Test cell for use with medical diagnostic instrument |
US20060148096A1 (en) * | 2002-11-05 | 2006-07-06 | Jina Arvind N | Assay device, system and method |
US7208071B2 (en) | 2000-11-01 | 2007-04-24 | Rosemount Analytical Inc. | Amperometric sensor for low level dissolved oxygen with self-depleting sensor design |
US20080112852A1 (en) * | 2002-04-25 | 2008-05-15 | Neel Gary T | Test Strips and System for Measuring Analyte Levels in a Fluid Sample |
US20090090623A1 (en) * | 2007-05-21 | 2009-04-09 | Delta Electronics, Inc. | Biosensor having integrated heating element and electrode with metallic catalyst |
US20090093735A1 (en) * | 2006-03-29 | 2009-04-09 | Stephan Korner | Test unit and test system for analyzing body fluids |
US20090145775A1 (en) * | 2007-12-10 | 2009-06-11 | Bayer Healthcare Llc | Reagents and methods for detecting analytes |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US20100012049A1 (en) * | 2006-04-12 | 2010-01-21 | Jms Co., Ltd | Cavitation heating system and method |
US7666149B2 (en) | 1997-12-04 | 2010-02-23 | Peliken Technologies, Inc. | Cassette of lancet cartridges for sampling blood |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7682318B2 (en) | 2001-06-12 | 2010-03-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
US7699791B2 (en) | 2001-06-12 | 2010-04-20 | Pelikan Technologies, Inc. | Method and apparatus for improving success rate of blood yield from a fingerstick |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7731729B2 (en) | 2002-04-19 | 2010-06-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
US7766846B2 (en) | 2008-01-28 | 2010-08-03 | Roche Diagnostics Operations, Inc. | Rapid blood expression and sampling |
EP2213231A1 (en) | 2009-01-30 | 2010-08-04 | Roche Diagnostics GmbH | Integrated body fluid meter and lancing device |
US7780631B2 (en) | 1998-03-30 | 2010-08-24 | Pelikan Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US7819822B2 (en) | 2004-03-06 | 2010-10-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US7833171B2 (en) | 2002-04-19 | 2010-11-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7850622B2 (en) | 2001-06-12 | 2010-12-14 | Pelikan Technologies, Inc. | Tissue penetration device |
US7862520B2 (en) | 2002-04-19 | 2011-01-04 | Pelikan Technologies, Inc. | Body fluid sampling module with a continuous compression tissue interface surface |
US7862696B2 (en) | 2006-09-22 | 2011-01-04 | Bayer Healthcare Llc | Biosensor system having enhanced stability and hematocrit performance |
WO2011000527A2 (en) | 2009-06-29 | 2011-01-06 | Roche Diagnostics Gmbh | Modular diabetes management systems |
US7874994B2 (en) | 2002-04-19 | 2011-01-25 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7901365B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
WO2011029567A1 (en) | 2009-09-09 | 2011-03-17 | Roche Diagnostics Gmbh | Storage containers for test elements |
US7909777B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7914465B2 (en) | 2002-04-19 | 2011-03-29 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
EP2339337A2 (en) | 2009-12-23 | 2011-06-29 | Roche Diagnostics GmbH | System for reading analyte test elements and for other uses |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7988645B2 (en) | 2001-06-12 | 2011-08-02 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
WO2011092010A1 (en) | 2010-01-29 | 2011-08-04 | Roche Diagnostics Gmbh | Electrode arrangements for biosensors |
US8000762B2 (en) | 2004-03-06 | 2011-08-16 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US8007446B2 (en) | 2002-04-19 | 2011-08-30 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8007656B2 (en) | 2003-10-24 | 2011-08-30 | Bayer Healthcare Llc | Enzymatic electrochemical biosensor |
US8026104B2 (en) | 2006-10-24 | 2011-09-27 | Bayer Healthcare Llc | Transient decay amperometry |
US8079960B2 (en) | 2002-04-19 | 2011-12-20 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
WO2012072251A1 (en) | 2010-12-02 | 2012-06-07 | Roche Diagnostics Gmbh | Test element ejection mechanism for a meter |
US8197421B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
WO2012084194A1 (en) | 2010-12-22 | 2012-06-28 | Roche Diagnostics Gmbh | Systems and methods to compensate for sources of error during electrochemical testing |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8262614B2 (en) | 2003-05-30 | 2012-09-11 | Pelikan Technologies, Inc. | Method and apparatus for fluid injection |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US8337421B2 (en) | 2001-06-12 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8404100B2 (en) | 2005-09-30 | 2013-03-26 | Bayer Healthcare Llc | Gated voltammetry |
US8425757B2 (en) | 2005-07-20 | 2013-04-23 | Bayer Healthcare Llc | Gated amperometry |
US8435190B2 (en) | 2002-04-19 | 2013-05-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
WO2013079177A1 (en) | 2011-11-28 | 2013-06-06 | Roche Diagnostics Gmbh | Insert component for storage container for biosensor test elements |
US8556829B2 (en) | 2002-04-19 | 2013-10-15 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8696880B2 (en) | 2004-02-06 | 2014-04-15 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8721671B2 (en) | 2001-06-12 | 2014-05-13 | Sanofi-Aventis Deutschland Gmbh | Electric lancet actuator |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
WO2014140172A1 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same |
WO2014140164A1 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of using information from recovery pulses in electrochemical analyte measurements as well as devices, apparatuses and systems incorporating the same |
WO2014140177A2 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of detecting high antioxidant levels during electrochemical measurements and failsafing an analyte concentration therefrom as well as devices, apparatuses and systems incorporting the same |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
WO2014025415A3 (en) * | 2012-08-08 | 2015-06-18 | Scanadu Incorporated | Quantitative colormetric analysis of biological analytes in an automatically calibrated environment |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US9285323B2 (en) | 2012-08-08 | 2016-03-15 | Scanadu Incorporated | Quantifying color changes of chemical test pads induced concentrations of biological analytes under different lighting conditions |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9528941B2 (en) | 2012-08-08 | 2016-12-27 | Scanadu Incorporated | Method and apparatus for determining analyte concentration by quantifying and interpreting color information captured in a continuous or periodic manner |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9863811B2 (en) | 2014-08-15 | 2018-01-09 | Scanadu Incorporated | Precision luxmeter methods for digital cameras to quantify colors in uncontrolled lighting environments |
EP3385706A1 (en) | 2013-03-15 | 2018-10-10 | Roche Diabetes Care GmbH | Methods of scaling data used to construct biosensor algorithms as well as devices, apparatuses and systems incorporating the same |
US10451577B2 (en) | 2016-03-16 | 2019-10-22 | Arkray, Inc. | Substance measuring method and measuring apparatus using electrochemical biosensor |
US11230727B2 (en) | 2016-10-05 | 2022-01-25 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
Citations (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838033A (en) * | 1971-09-09 | 1974-09-24 | Hoffmann La Roche | Enzyme electrode |
US3925183A (en) * | 1972-06-16 | 1975-12-09 | Energetics Science | Gas detecting and quantitative measuring device |
US4005002A (en) * | 1973-08-06 | 1977-01-25 | Hoffmann-La Roche Inc. | Apparatus for measuring substrate concentrations |
US4169779A (en) * | 1978-12-26 | 1979-10-02 | Catalyst Research Corporation | Electrochemical cell for the detection of hydrogen sulfide |
JPS5510584A (en) * | 1978-07-10 | 1980-01-25 | Matsushita Electric Ind Co Ltd | Enzyme electrode and its manufacture |
US4217196A (en) * | 1978-05-30 | 1980-08-12 | Albert Huch | Dish-electrode concentration meter with detachable transducer |
US4224125A (en) * | 1977-09-28 | 1980-09-23 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
US4225410A (en) * | 1978-12-04 | 1980-09-30 | Technicon Instruments Corporation | Integrated array of electrochemical sensors |
US4321123A (en) * | 1978-04-21 | 1982-03-23 | Matsushita Electric Industrial Co., Ltd. | Coenzyme immobilized electrode |
JPS5798853A (en) * | 1980-12-12 | 1982-06-19 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4392933A (en) * | 1978-10-31 | 1983-07-12 | Matsushita Electric Industrial Co., Ltd. | Electrochemical measuring apparatus comprising enzyme electrode |
US4407959A (en) * | 1980-10-29 | 1983-10-04 | Fuji Electric Co., Ltd. | Blood sugar analyzing apparatus |
US4420564A (en) * | 1980-11-21 | 1983-12-13 | Fuji Electric Company, Ltd. | Blood sugar analyzer having fixed enzyme membrane sensor |
US4431507A (en) * | 1981-01-14 | 1984-02-14 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
JPS59166852A (en) * | 1983-03-11 | 1984-09-20 | Matsushita Electric Ind Co Ltd | Biosensor |
EP0136362A1 (en) * | 1983-03-11 | 1985-04-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
GB2154003A (en) * | 1983-12-16 | 1985-08-29 | Genetics Int Inc | Diagnostic aid |
JPS60173457A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60173458A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60173459A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
US4545382A (en) * | 1981-10-23 | 1985-10-08 | Genetics International, Inc. | Sensor for components of a liquid mixture |
JPS60211350A (en) * | 1984-04-06 | 1985-10-23 | Matsushita Electric Ind Co Ltd | Biosensor |
US4579643A (en) * | 1983-11-18 | 1986-04-01 | Ngk Insulators, Ltd. | Electrochemical device |
JPS6190050A (en) * | 1984-10-09 | 1986-05-08 | Matsushita Electric Ind Co Ltd | Production of chip for biosensor |
JPS6191558A (en) * | 1984-10-12 | 1986-05-09 | Matsushita Electric Ind Co Ltd | Biosensor |
WO1986004926A1 (en) * | 1985-02-21 | 1986-08-28 | Genetics International Inc. | Assay for degradable substrates by electrochemical detection of redox species |
JPS61294356A (en) * | 1985-06-21 | 1986-12-25 | Matsushita Electric Ind Co Ltd | Biosensor |
EP0206218A2 (en) * | 1985-06-28 | 1986-12-30 | Miles Inc. | Electrode for electrochemical sensors |
WO1986007632A1 (en) * | 1985-06-21 | 1986-12-31 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of manufacturing same |
US4654197A (en) * | 1983-10-18 | 1987-03-31 | Aktiebolaget Leo | Cuvette for sampling and analysis |
US4655901A (en) * | 1983-08-09 | 1987-04-07 | Ngk Insulators, Ltd. | Oxygen sensor element |
JPS62156553A (en) * | 1985-12-27 | 1987-07-11 | Daikin Ind Ltd | Concentration measuring instrument |
US4682602A (en) * | 1981-05-07 | 1987-07-28 | Ottosensor Corporation | Probe for medical application |
EP0230786A1 (en) * | 1985-12-24 | 1987-08-05 | MediSense, Inc. | Assay for cholesterol and derivatives thereof |
EP0241309A2 (en) * | 1986-04-10 | 1987-10-14 | MediSense, Inc. | Measurement of electroactive species in solution |
US4711245A (en) * | 1983-05-05 | 1987-12-08 | Genetics International, Inc. | Sensor for components of a liquid mixture |
JPS633249A (en) * | 1986-06-23 | 1988-01-08 | Matsushita Electric Ind Co Ltd | Biosensor |
EP0255291A1 (en) * | 1986-07-23 | 1988-02-03 | Unilever Plc | Method and apparatus for electrochemical measurements |
JPS6358149A (en) * | 1986-08-28 | 1988-03-12 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS63128252A (en) * | 1986-11-18 | 1988-05-31 | Matsushita Electric Ind Co Ltd | Biosensor |
US4758323A (en) * | 1983-05-05 | 1988-07-19 | Genetics International, Inc. | Assay systems using more than one enzyme |
US4796014A (en) * | 1987-03-24 | 1989-01-03 | Chia Jack T | Device for detecting urine in diapers |
US4810633A (en) * | 1984-06-04 | 1989-03-07 | Miles Inc. | Enzymatic ethanol test |
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
US4830959A (en) * | 1985-11-11 | 1989-05-16 | Medisense, Inc. | Electrochemical enzymic assay procedures |
US4836904A (en) * | 1985-03-28 | 1989-06-06 | Medisense, Inc. | Graphite electrode with modified surface |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
EP0170375B1 (en) * | 1984-06-13 | 1990-05-16 | Unilever Plc | Devices for use in chemical test procedures |
US4927516A (en) * | 1986-06-27 | 1990-05-22 | Terumo Kabushiki Kaisha | Enzyme sensor |
US4935106A (en) * | 1985-11-15 | 1990-06-19 | Smithkline Diagnostics, Inc. | Ion selective/enzymatic electrode medical analyzer device and method of use |
US4935105A (en) * | 1987-02-24 | 1990-06-19 | Imperial Chemical Industries Plc | Methods of operating enzyme electrode sensors |
US4948727A (en) * | 1984-10-12 | 1990-08-14 | Medisense, Inc. | Chemical sensor |
US4952300A (en) * | 1987-03-19 | 1990-08-28 | Howard Diamond | Multiparameter analytical electrode structure and method of measurement |
US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
US4970145A (en) * | 1986-05-27 | 1990-11-13 | Cambridge Life Sciences Plc | Immobilized enzyme electrodes |
US4995402A (en) * | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
US5030310A (en) * | 1985-06-28 | 1991-07-09 | Miles Inc. | Electrode for electrochemical sensors |
US5049487A (en) * | 1986-08-13 | 1991-09-17 | Lifescan, Inc. | Automated initiation of timing of reflectance readings |
US5140393A (en) * | 1985-10-08 | 1992-08-18 | Sharp Kabushiki Kaisha | Sensor device |
US5141868A (en) * | 1984-06-13 | 1992-08-25 | Internationale Octrooi Maatschappij "Octropa" Bv | Device for use in chemical test procedures |
US5171689A (en) * | 1984-11-08 | 1992-12-15 | Matsushita Electric Industrial Co., Ltd. | Solid state bio-sensor |
EP0785901A1 (en) * | 1994-10-14 | 1997-07-30 | Ier | Cartridge and roller for a consumable ribbon, receiving apparatus, and rotational roller coupling method |
EP0786361A1 (en) * | 1996-01-26 | 1997-07-30 | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN-MICHELIN & CIE | Method for processing signals in a tyre monitoring system of a running vehicle |
EP1251371A1 (en) * | 2000-01-27 | 2002-10-23 | Idemitsu Petrochemical Co., Ltd. | Light guide plates and process for producing the same |
EP1279581A1 (en) * | 2001-07-16 | 2003-01-29 | Siemens Aktiengesellschaft | External train length measuring device |
EP1363621A1 (en) * | 2000-11-30 | 2003-11-26 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
-
1996
- 1996-07-12 US US08/679,312 patent/USRE36268E/en not_active Expired - Lifetime
Patent Citations (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838033A (en) * | 1971-09-09 | 1974-09-24 | Hoffmann La Roche | Enzyme electrode |
US3925183A (en) * | 1972-06-16 | 1975-12-09 | Energetics Science | Gas detecting and quantitative measuring device |
US4005002A (en) * | 1973-08-06 | 1977-01-25 | Hoffmann-La Roche Inc. | Apparatus for measuring substrate concentrations |
US4224125A (en) * | 1977-09-28 | 1980-09-23 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
US4321123A (en) * | 1978-04-21 | 1982-03-23 | Matsushita Electric Industrial Co., Ltd. | Coenzyme immobilized electrode |
US4217196A (en) * | 1978-05-30 | 1980-08-12 | Albert Huch | Dish-electrode concentration meter with detachable transducer |
JPS5510584A (en) * | 1978-07-10 | 1980-01-25 | Matsushita Electric Ind Co Ltd | Enzyme electrode and its manufacture |
US4392933A (en) * | 1978-10-31 | 1983-07-12 | Matsushita Electric Industrial Co., Ltd. | Electrochemical measuring apparatus comprising enzyme electrode |
US4225410A (en) * | 1978-12-04 | 1980-09-30 | Technicon Instruments Corporation | Integrated array of electrochemical sensors |
US4169779A (en) * | 1978-12-26 | 1979-10-02 | Catalyst Research Corporation | Electrochemical cell for the detection of hydrogen sulfide |
US4407959A (en) * | 1980-10-29 | 1983-10-04 | Fuji Electric Co., Ltd. | Blood sugar analyzing apparatus |
US4420564A (en) * | 1980-11-21 | 1983-12-13 | Fuji Electric Company, Ltd. | Blood sugar analyzer having fixed enzyme membrane sensor |
JPS5798853A (en) * | 1980-12-12 | 1982-06-19 | Matsushita Electric Ind Co Ltd | Enzyme electrode |
US4431507A (en) * | 1981-01-14 | 1984-02-14 | Matsushita Electric Industrial Co., Ltd. | Enzyme electrode |
US4682602A (en) * | 1981-05-07 | 1987-07-28 | Ottosensor Corporation | Probe for medical application |
US4545382A (en) * | 1981-10-23 | 1985-10-08 | Genetics International, Inc. | Sensor for components of a liquid mixture |
JPS59166852A (en) * | 1983-03-11 | 1984-09-20 | Matsushita Electric Ind Co Ltd | Biosensor |
EP0136362A1 (en) * | 1983-03-11 | 1985-04-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US4711245A (en) * | 1983-05-05 | 1987-12-08 | Genetics International, Inc. | Sensor for components of a liquid mixture |
US4758323A (en) * | 1983-05-05 | 1988-07-19 | Genetics International, Inc. | Assay systems using more than one enzyme |
US4655901A (en) * | 1983-08-09 | 1987-04-07 | Ngk Insulators, Ltd. | Oxygen sensor element |
US4654197A (en) * | 1983-10-18 | 1987-03-31 | Aktiebolaget Leo | Cuvette for sampling and analysis |
US4579643A (en) * | 1983-11-18 | 1986-04-01 | Ngk Insulators, Ltd. | Electrochemical device |
GB2154003A (en) * | 1983-12-16 | 1985-08-29 | Genetics Int Inc | Diagnostic aid |
JPS60173458A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60173459A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60173457A (en) * | 1984-02-20 | 1985-09-06 | Matsushita Electric Ind Co Ltd | Biosensor |
JPS60211350A (en) * | 1984-04-06 | 1985-10-23 | Matsushita Electric Ind Co Ltd | Biosensor |
US4810633A (en) * | 1984-06-04 | 1989-03-07 | Miles Inc. | Enzymatic ethanol test |
US5141868A (en) * | 1984-06-13 | 1992-08-25 | Internationale Octrooi Maatschappij "Octropa" Bv | Device for use in chemical test procedures |
EP0170375B1 (en) * | 1984-06-13 | 1990-05-16 | Unilever Plc | Devices for use in chemical test procedures |
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
EP0177743B1 (en) * | 1984-08-31 | 1991-11-06 | Shimadzu Corporation | Enzyme electrodes |
JPS6190050A (en) * | 1984-10-09 | 1986-05-08 | Matsushita Electric Ind Co Ltd | Production of chip for biosensor |
JPS6191558A (en) * | 1984-10-12 | 1986-05-09 | Matsushita Electric Ind Co Ltd | Biosensor |
US4948727A (en) * | 1984-10-12 | 1990-08-14 | Medisense, Inc. | Chemical sensor |
US5171689A (en) * | 1984-11-08 | 1992-12-15 | Matsushita Electric Industrial Co., Ltd. | Solid state bio-sensor |
US4820636A (en) * | 1985-02-21 | 1989-04-11 | Medisense, Inc. | Electrochemical assay for cis-diols |
WO1986004926A1 (en) * | 1985-02-21 | 1986-08-28 | Genetics International Inc. | Assay for degradable substrates by electrochemical detection of redox species |
US4836904A (en) * | 1985-03-28 | 1989-06-06 | Medisense, Inc. | Graphite electrode with modified surface |
EP0230472A1 (en) * | 1985-06-21 | 1987-08-05 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of manufacturing same |
US4897173A (en) * | 1985-06-21 | 1990-01-30 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for making the same |
WO1986007632A1 (en) * | 1985-06-21 | 1986-12-31 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method of manufacturing same |
JPS61294356A (en) * | 1985-06-21 | 1986-12-25 | Matsushita Electric Ind Co Ltd | Biosensor |
US4938860A (en) * | 1985-06-28 | 1990-07-03 | Miles Inc. | Electrode for electrochemical sensors |
US5030310A (en) * | 1985-06-28 | 1991-07-09 | Miles Inc. | Electrode for electrochemical sensors |
EP0206218A2 (en) * | 1985-06-28 | 1986-12-30 | Miles Inc. | Electrode for electrochemical sensors |
US5140393A (en) * | 1985-10-08 | 1992-08-18 | Sharp Kabushiki Kaisha | Sensor device |
US4830959A (en) * | 1985-11-11 | 1989-05-16 | Medisense, Inc. | Electrochemical enzymic assay procedures |
US4935106A (en) * | 1985-11-15 | 1990-06-19 | Smithkline Diagnostics, Inc. | Ion selective/enzymatic electrode medical analyzer device and method of use |
EP0230786A1 (en) * | 1985-12-24 | 1987-08-05 | MediSense, Inc. | Assay for cholesterol and derivatives thereof |
JPS62156553A (en) * | 1985-12-27 | 1987-07-11 | Daikin Ind Ltd | Concentration measuring instrument |
EP0241309A2 (en) * | 1986-04-10 | 1987-10-14 | MediSense, Inc. | Measurement of electroactive species in solution |
US4970145A (en) * | 1986-05-27 | 1990-11-13 | Cambridge Life Sciences Plc | Immobilized enzyme electrodes |
US4959305A (en) * | 1986-06-18 | 1990-09-25 | Miles Inc. | Reversible immobilization of assay reagents in a multizone test device |
JPS633249A (en) * | 1986-06-23 | 1988-01-08 | Matsushita Electric Ind Co Ltd | Biosensor |
US4927516A (en) * | 1986-06-27 | 1990-05-22 | Terumo Kabushiki Kaisha | Enzyme sensor |
EP0255291A1 (en) * | 1986-07-23 | 1988-02-03 | Unilever Plc | Method and apparatus for electrochemical measurements |
US5049487A (en) * | 1986-08-13 | 1991-09-17 | Lifescan, Inc. | Automated initiation of timing of reflectance readings |
JPS6358149A (en) * | 1986-08-28 | 1988-03-12 | Matsushita Electric Ind Co Ltd | Biosensor |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
JPS63128252A (en) * | 1986-11-18 | 1988-05-31 | Matsushita Electric Ind Co Ltd | Biosensor |
US4935105A (en) * | 1987-02-24 | 1990-06-19 | Imperial Chemical Industries Plc | Methods of operating enzyme electrode sensors |
US4952300A (en) * | 1987-03-19 | 1990-08-28 | Howard Diamond | Multiparameter analytical electrode structure and method of measurement |
US4796014A (en) * | 1987-03-24 | 1989-01-03 | Chia Jack T | Device for detecting urine in diapers |
US4995402A (en) * | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
EP0785901A1 (en) * | 1994-10-14 | 1997-07-30 | Ier | Cartridge and roller for a consumable ribbon, receiving apparatus, and rotational roller coupling method |
EP0786361A1 (en) * | 1996-01-26 | 1997-07-30 | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN-MICHELIN & CIE | Method for processing signals in a tyre monitoring system of a running vehicle |
EP1251371A1 (en) * | 2000-01-27 | 2002-10-23 | Idemitsu Petrochemical Co., Ltd. | Light guide plates and process for producing the same |
EP1363621A1 (en) * | 2000-11-30 | 2003-11-26 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
EP1279581A1 (en) * | 2001-07-16 | 2003-01-29 | Siemens Aktiengesellschaft | External train length measuring device |
Non-Patent Citations (15)
Title |
---|
Biochemica Information; pp. 18, 19, 27 and 28 (J. Keesey, ed., Boehringer Mannheim Biochemicals, 1987) no month available. * |
Laboratory Techniques in Electroanalytical Chemistry; pp. 51 64 and 124 (Kissinger and Heineman, eds., 1984) no month available. * |
Laboratory Techniques in Electroanalytical Chemistry; pp. 51-64 and 124 (Kissinger and Heineman, eds., 1984) no month available. |
Myland, Janice C. and Oldham, Keith B.; "Membrane-Covered Oxygen Sensors: An Exact Treatment of the Switch-on Transient"; Aug. 1984; pp. 1815-1823; J. Electrochem. Soc. |
Myland, Janice C. and Oldham, Keith B.; Membrane Covered Oxygen Sensors: An Exact Treatment of the Switch on Transient ; Aug. 1984; pp. 1815 1823; J. Electrochem. Soc. * |
Talbott et al.; "A New Microchemical Approach to Amperometric Analysis", Feb. 1988, vol. 37, pp. 5-12, Microchemical Journal. |
Talbott et al.; A New Microchemical Approach to Amperometric Analysis , Feb. 1988, vol. 37, pp. 5 12, Microchemical Journal. * |
Talbott, Jonathan Lee; "Enzymatic Amperometry of Glucose"; 1988; Pennsylvania State University (Thesis for Doctor of Philosophy in Chemistry) no month available. |
Talbott, Jonathan Lee; Enzymatic Amperometry of Glucose ; 1988; Pennsylvania State University (Thesis for Doctor of Philosophy in Chemistry) no month available. * |
Tokuda, Koichi; "Measurement of Current--Potential Curves"; 1986; pp. 471-475; Denki Kagaku (English Translation Included) no month available. |
Tokuda, Koichi; Measurement of Current Potential Curves ; 1986; pp. 471 475; Denki Kagaku (English Translation Included) no month available. * |
Van Nostrand Reinhold Encyclopedia of Chemistry; pp. 149 150 (4th edition 1984) no month available. * |
Van Nostrand Reinhold Encyclopedia of Chemistry; pp. 149-150 (4th edition 1984) no month available. |
Williams et al.; "Electrochemical--Enzymatic Analysis of Blood Glucose and Lactate"; Jan. 1970; pp. 118-121; Analytical Chemistry. |
Williams et al.; Electrochemical Enzymatic Analysis of Blood Glucose and Lactate ; Jan. 1970; pp. 118 121; Analytical Chemistry. * |
Cited By (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666149B2 (en) | 1997-12-04 | 2010-02-23 | Peliken Technologies, Inc. | Cassette of lancet cartridges for sampling blood |
US7780631B2 (en) | 1998-03-30 | 2010-08-24 | Pelikan Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8439872B2 (en) | 1998-03-30 | 2013-05-14 | Sanofi-Aventis Deutschland Gmbh | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US7041206B2 (en) | 2000-03-09 | 2006-05-09 | Clinical Analysis Corporation | Medical diagnostic system |
US20010045355A1 (en) * | 2000-03-09 | 2001-11-29 | Clinical Analysis Corporation | Medical diagnostic system |
US7208071B2 (en) | 2000-11-01 | 2007-04-24 | Rosemount Analytical Inc. | Amperometric sensor for low level dissolved oxygen with self-depleting sensor design |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US20060108218A1 (en) * | 2001-03-05 | 2006-05-25 | Clinical Analysis Corporation | Test cell for use with medical diagnostic instrument |
US20050067737A1 (en) * | 2001-03-23 | 2005-03-31 | Craig Rappin | Method of making sensor |
US6572745B2 (en) | 2001-03-23 | 2003-06-03 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
US6576102B1 (en) | 2001-03-23 | 2003-06-10 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
US8360991B2 (en) | 2001-06-12 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9694144B2 (en) | 2001-06-12 | 2017-07-04 | Sanofi-Aventis Deutschland Gmbh | Sampling module device and method |
US8641643B2 (en) | 2001-06-12 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Sampling module device and method |
US8622930B2 (en) | 2001-06-12 | 2014-01-07 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8721671B2 (en) | 2001-06-12 | 2014-05-13 | Sanofi-Aventis Deutschland Gmbh | Electric lancet actuator |
US8382683B2 (en) | 2001-06-12 | 2013-02-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8845550B2 (en) | 2001-06-12 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7682318B2 (en) | 2001-06-12 | 2010-03-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7699791B2 (en) | 2001-06-12 | 2010-04-20 | Pelikan Technologies, Inc. | Method and apparatus for improving success rate of blood yield from a fingerstick |
US8337421B2 (en) | 2001-06-12 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8282577B2 (en) | 2001-06-12 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8216154B2 (en) | 2001-06-12 | 2012-07-10 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8679033B2 (en) | 2001-06-12 | 2014-03-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8211037B2 (en) | 2001-06-12 | 2012-07-03 | Pelikan Technologies, Inc. | Tissue penetration device |
US8206317B2 (en) | 2001-06-12 | 2012-06-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8206319B2 (en) | 2001-06-12 | 2012-06-26 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8123700B2 (en) | 2001-06-12 | 2012-02-28 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US8016774B2 (en) | 2001-06-12 | 2011-09-13 | Pelikan Technologies, Inc. | Tissue penetration device |
US7988645B2 (en) | 2001-06-12 | 2011-08-02 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US7981055B2 (en) | 2001-06-12 | 2011-07-19 | Pelikan Technologies, Inc. | Tissue penetration device |
US7909775B2 (en) | 2001-06-12 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7850622B2 (en) | 2001-06-12 | 2010-12-14 | Pelikan Technologies, Inc. | Tissue penetration device |
US9802007B2 (en) | 2001-06-12 | 2017-10-31 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9937298B2 (en) | 2001-06-12 | 2018-04-10 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
US9560993B2 (en) | 2001-11-21 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7731729B2 (en) | 2002-04-19 | 2010-06-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9907502B2 (en) | 2002-04-19 | 2018-03-06 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9839386B2 (en) | 2002-04-19 | 2017-12-12 | Sanofi-Aventis Deustschland Gmbh | Body fluid sampling device with capacitive sensor |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9724021B2 (en) | 2002-04-19 | 2017-08-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9498160B2 (en) | 2002-04-19 | 2016-11-22 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US9339612B2 (en) | 2002-04-19 | 2016-05-17 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7833171B2 (en) | 2002-04-19 | 2010-11-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7862520B2 (en) | 2002-04-19 | 2011-01-04 | Pelikan Technologies, Inc. | Body fluid sampling module with a continuous compression tissue interface surface |
US9186468B2 (en) | 2002-04-19 | 2015-11-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9089294B2 (en) | 2002-04-19 | 2015-07-28 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7874994B2 (en) | 2002-04-19 | 2011-01-25 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7875047B2 (en) | 2002-04-19 | 2011-01-25 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7901365B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9072842B2 (en) | 2002-04-19 | 2015-07-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7909777B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8905945B2 (en) | 2002-04-19 | 2014-12-09 | Dominique M. Freeman | Method and apparatus for penetrating tissue |
US7914465B2 (en) | 2002-04-19 | 2011-03-29 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7938787B2 (en) | 2002-04-19 | 2011-05-10 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8845549B2 (en) | 2002-04-19 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Method for penetrating tissue |
US8808201B2 (en) | 2002-04-19 | 2014-08-19 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7988644B2 (en) | 2002-04-19 | 2011-08-02 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8690796B2 (en) | 2002-04-19 | 2014-04-08 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8636673B2 (en) | 2002-04-19 | 2014-01-28 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8007446B2 (en) | 2002-04-19 | 2011-08-30 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8562545B2 (en) | 2002-04-19 | 2013-10-22 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8556829B2 (en) | 2002-04-19 | 2013-10-15 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8496601B2 (en) | 2002-04-19 | 2013-07-30 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8062231B2 (en) | 2002-04-19 | 2011-11-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8491500B2 (en) | 2002-04-19 | 2013-07-23 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8079960B2 (en) | 2002-04-19 | 2011-12-20 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8435190B2 (en) | 2002-04-19 | 2013-05-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8157748B2 (en) | 2002-04-19 | 2012-04-17 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8430828B2 (en) | 2002-04-19 | 2013-04-30 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8414503B2 (en) | 2002-04-19 | 2013-04-09 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US8197421B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8197423B2 (en) | 2002-04-19 | 2012-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8202231B2 (en) | 2002-04-19 | 2012-06-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8403864B2 (en) | 2002-04-19 | 2013-03-26 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8388551B2 (en) | 2002-04-19 | 2013-03-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for multi-use body fluid sampling device with sterility barrier release |
US8382682B2 (en) | 2002-04-19 | 2013-02-26 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8366637B2 (en) | 2002-04-19 | 2013-02-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8235915B2 (en) | 2002-04-19 | 2012-08-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US20040182703A1 (en) * | 2002-04-25 | 2004-09-23 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US6953693B2 (en) | 2002-04-25 | 2005-10-11 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20040104131A1 (en) * | 2002-04-25 | 2004-06-03 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20050045476A1 (en) * | 2002-04-25 | 2005-03-03 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US20040094432A1 (en) * | 2002-04-25 | 2004-05-20 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US7819161B2 (en) | 2002-04-25 | 2010-10-26 | Nipro Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US6964871B2 (en) | 2002-04-25 | 2005-11-15 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US6959247B2 (en) | 2002-04-25 | 2005-10-25 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US7160251B2 (en) | 2002-04-25 | 2007-01-09 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US6743635B2 (en) | 2002-04-25 | 2004-06-01 | Home Diagnostics, Inc. | System and methods for blood glucose sensing |
US20080112852A1 (en) * | 2002-04-25 | 2008-05-15 | Neel Gary T | Test Strips and System for Measuring Analyte Levels in a Fluid Sample |
US20070089987A1 (en) * | 2002-04-25 | 2007-04-26 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US6946299B2 (en) | 2002-04-25 | 2005-09-20 | Home Diagnostics, Inc. | Systems and methods for blood glucose sensing |
US7534583B2 (en) | 2002-05-17 | 2009-05-19 | Oxford Biosencors Limited | Analyte measurement |
US20050164329A1 (en) * | 2002-05-17 | 2005-07-28 | Wallace-Davis Emma N.K. | Analyte measurement |
US20040079652A1 (en) * | 2002-08-27 | 2004-04-29 | Bayer Healthcare Llc | Methods of determining glucose concentration in whole blood samples |
US20060148096A1 (en) * | 2002-11-05 | 2006-07-06 | Jina Arvind N | Assay device, system and method |
US7670853B2 (en) | 2002-11-05 | 2010-03-02 | Abbott Diabetes Care Inc. | Assay device, system and method |
US20100190268A1 (en) * | 2002-11-05 | 2010-07-29 | Abbott Diabetes Care Inc. | Assay Device, System and Method |
US8079961B2 (en) | 2002-11-06 | 2011-12-20 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US7572237B2 (en) | 2002-11-06 | 2009-08-11 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US9060727B2 (en) | 2002-11-06 | 2015-06-23 | Abbott Diabetes Care Inc. | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US20040138588A1 (en) * | 2002-11-06 | 2004-07-15 | Saikley Charles R | Automatic biological analyte testing meter with integrated lancing device and methods of use |
US20050147811A1 (en) * | 2002-12-17 | 2005-07-07 | Richard Baron | Adhesive articles which contain at least one hydrophilic or hydrophobic layer, method for making and uses for same |
US7175897B2 (en) | 2002-12-17 | 2007-02-13 | Avery Dennison Corporation | Adhesive articles which contain at least one hydrophilic or hydrophobic layer, method for making and uses for same |
US9034639B2 (en) | 2002-12-30 | 2015-05-19 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
US8262614B2 (en) | 2003-05-30 | 2012-09-11 | Pelikan Technologies, Inc. | Method and apparatus for fluid injection |
US8251921B2 (en) | 2003-06-06 | 2012-08-28 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US10034628B2 (en) | 2003-06-11 | 2018-07-31 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US9144401B2 (en) | 2003-06-11 | 2015-09-29 | Sanofi-Aventis Deutschland Gmbh | Low pain penetrating member |
US20040253367A1 (en) * | 2003-06-12 | 2004-12-16 | Wogoman Frank W. | Sensor format and construction method for capillary-filled diagnostic sensors |
US7544277B2 (en) * | 2003-06-12 | 2009-06-09 | Bayer Healthcare, Llc | Electrochemical test sensors |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US8945910B2 (en) | 2003-09-29 | 2015-02-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US8691073B2 (en) | 2003-10-24 | 2014-04-08 | Bayer Healthcare Llc | Enzymatic electrochemical biosensor |
US9803228B2 (en) | 2003-10-24 | 2017-10-31 | Ascensia Diabetes Care Holdings Ag | Electrochemical sensor strip |
US9157111B2 (en) | 2003-10-24 | 2015-10-13 | Bayer Healthcare Llc | Method of making an electrochemical sensor strip |
US10982251B2 (en) | 2003-10-24 | 2021-04-20 | Ascensia Diabetes Care Holdings Ag | Method of making an electrochemical sensor strip |
US10457971B2 (en) | 2003-10-24 | 2019-10-29 | Ascensia Diabetes Care Holdings Ag | Method of making an electrochemical sensor strip |
US8007656B2 (en) | 2003-10-24 | 2011-08-30 | Bayer Healthcare Llc | Enzymatic electrochemical biosensor |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US9561000B2 (en) | 2003-12-31 | 2017-02-07 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US8296918B2 (en) | 2003-12-31 | 2012-10-30 | Sanofi-Aventis Deutschland Gmbh | Method of manufacturing a fluid sampling device with improved analyte detecting member configuration |
US8696880B2 (en) | 2004-02-06 | 2014-04-15 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US9410917B2 (en) | 2004-02-06 | 2016-08-09 | Ascensia Diabetes Care Holdings Ag | Method of using a biosensor |
US10067082B2 (en) | 2004-02-06 | 2018-09-04 | Ascensia Diabetes Care Holdings Ag | Biosensor for determining an analyte concentration |
US20050194265A1 (en) * | 2004-03-03 | 2005-09-08 | Apex Biotechnology Corp. | Method for reducing measuring bias in amperometric biosensors |
US8000762B2 (en) | 2004-03-06 | 2011-08-16 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US9022952B2 (en) | 2004-03-06 | 2015-05-05 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US7819822B2 (en) | 2004-03-06 | 2010-10-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US8369918B2 (en) | 2004-03-06 | 2013-02-05 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
EP2705792A1 (en) | 2004-03-06 | 2014-03-12 | F. Hoffmann-La Roche AG | Body fluid sampling device |
EP2727531A2 (en) | 2004-03-06 | 2014-05-07 | Roche Diagnostics GmbH | Body fluid sampling device |
US8162854B2 (en) | 2004-03-06 | 2012-04-24 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US8814808B2 (en) | 2004-03-06 | 2014-08-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US9261476B2 (en) | 2004-05-20 | 2016-02-16 | Sanofi Sa | Printable hydrogel for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US9820684B2 (en) | 2004-06-03 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8877035B2 (en) | 2005-07-20 | 2014-11-04 | Bayer Healthcare Llc | Gated amperometry methods |
US8425757B2 (en) | 2005-07-20 | 2013-04-23 | Bayer Healthcare Llc | Gated amperometry |
US9110013B2 (en) | 2005-09-30 | 2015-08-18 | Bayer Healthcare Llc | Gated voltammetry methods |
US8647489B2 (en) | 2005-09-30 | 2014-02-11 | Bayer Healthcare Llc | Gated voltammetry devices |
US9835582B2 (en) | 2005-09-30 | 2017-12-05 | Ascensia Diabetes Care Holdings Ag | Devices using gated voltammetry methods |
US10670553B2 (en) | 2005-09-30 | 2020-06-02 | Ascensia Diabetes Care Holdings Ag | Devices using gated voltammetry methods |
US8404100B2 (en) | 2005-09-30 | 2013-03-26 | Bayer Healthcare Llc | Gated voltammetry |
US11435312B2 (en) | 2005-09-30 | 2022-09-06 | Ascensia Diabetes Care Holdings Ag | Devices using gated voltammetry methods |
US20090093735A1 (en) * | 2006-03-29 | 2009-04-09 | Stephan Korner | Test unit and test system for analyzing body fluids |
US20100012049A1 (en) * | 2006-04-12 | 2010-01-21 | Jms Co., Ltd | Cavitation heating system and method |
US7862696B2 (en) | 2006-09-22 | 2011-01-04 | Bayer Healthcare Llc | Biosensor system having enhanced stability and hematocrit performance |
US10261044B2 (en) | 2006-09-22 | 2019-04-16 | Ascensia Diabetes Care Holdings Ag | Electrochemical test sensor |
US8702965B2 (en) | 2006-09-22 | 2014-04-22 | Bayer Healthcare Llc | Biosensor methods having enhanced stability and hematocrit performance |
US9239312B2 (en) | 2006-09-22 | 2016-01-19 | Bayer Healthcare Llc | Methods of determining analyte concentration having enhanced stability and hematocrit performance |
US20110115504A1 (en) * | 2006-09-22 | 2011-05-19 | Bayer Healthcare Llc | Biosensor Methods Having Enhanced Stability and Hematocrit Performance |
US9459229B2 (en) | 2006-09-22 | 2016-10-04 | Ascenia Diabetes Care Holdings AG | Electrochemical test sensor |
US8728299B2 (en) | 2006-09-22 | 2014-05-20 | Bayer Healthcare Llc | Biosensor performance increasing methods having enhanced stability and hematocrit performance |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9005527B2 (en) | 2006-10-24 | 2015-04-14 | Bayer Healthcare Llc | Transient decay amperometry biosensors |
US11091790B2 (en) | 2006-10-24 | 2021-08-17 | Ascensia Diabetes Care Holdings Ag | Determining analyte concentration from variant concentration distribution in measurable species |
US10190150B2 (en) | 2006-10-24 | 2019-01-29 | Ascensia Diabetes Care Holdings Ag | Determining analyte concentration from variant concentration distribution in measurable species |
US8026104B2 (en) | 2006-10-24 | 2011-09-27 | Bayer Healthcare Llc | Transient decay amperometry |
US8470604B2 (en) | 2006-10-24 | 2013-06-25 | Bayer Healthcare Llc | Transient decay amperometry |
US20090090623A1 (en) * | 2007-05-21 | 2009-04-09 | Delta Electronics, Inc. | Biosensor having integrated heating element and electrode with metallic catalyst |
US10696998B2 (en) | 2007-12-10 | 2020-06-30 | Ascensia Diabetes Care Holdings Ag | Reagents and methods for detecting analytes |
US20090145775A1 (en) * | 2007-12-10 | 2009-06-11 | Bayer Healthcare Llc | Reagents and methods for detecting analytes |
US11180790B2 (en) | 2007-12-10 | 2021-11-23 | Ascensia Diabetes Care Holdings Ag | Reagents and methods for detecting analytes |
US7766846B2 (en) | 2008-01-28 | 2010-08-03 | Roche Diagnostics Operations, Inc. | Rapid blood expression and sampling |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
EP2213231A1 (en) | 2009-01-30 | 2010-08-04 | Roche Diagnostics GmbH | Integrated body fluid meter and lancing device |
WO2011000527A2 (en) | 2009-06-29 | 2011-01-06 | Roche Diagnostics Gmbh | Modular diabetes management systems |
WO2011029567A1 (en) | 2009-09-09 | 2011-03-17 | Roche Diagnostics Gmbh | Storage containers for test elements |
EP2339337A2 (en) | 2009-12-23 | 2011-06-29 | Roche Diagnostics GmbH | System for reading analyte test elements and for other uses |
WO2011092010A1 (en) | 2010-01-29 | 2011-08-04 | Roche Diagnostics Gmbh | Electrode arrangements for biosensors |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
WO2012072251A1 (en) | 2010-12-02 | 2012-06-07 | Roche Diagnostics Gmbh | Test element ejection mechanism for a meter |
WO2012084194A1 (en) | 2010-12-22 | 2012-06-28 | Roche Diagnostics Gmbh | Systems and methods to compensate for sources of error during electrochemical testing |
WO2013079177A1 (en) | 2011-11-28 | 2013-06-06 | Roche Diagnostics Gmbh | Insert component for storage container for biosensor test elements |
EP3575790A2 (en) | 2011-11-28 | 2019-12-04 | Roche Diabetes Care GmbH | Insert component for storage container for biosensor test elements |
US9528941B2 (en) | 2012-08-08 | 2016-12-27 | Scanadu Incorporated | Method and apparatus for determining analyte concentration by quantifying and interpreting color information captured in a continuous or periodic manner |
US9285323B2 (en) | 2012-08-08 | 2016-03-15 | Scanadu Incorporated | Quantifying color changes of chemical test pads induced concentrations of biological analytes under different lighting conditions |
US9311520B2 (en) | 2012-08-08 | 2016-04-12 | Scanadu Incorporated | Method and apparatus for performing and quantifying color changes induced by specific concentrations of biological analytes in an automatically calibrated environment |
WO2014025415A3 (en) * | 2012-08-08 | 2015-06-18 | Scanadu Incorporated | Quantitative colormetric analysis of biological analytes in an automatically calibrated environment |
WO2014140164A1 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of using information from recovery pulses in electrochemical analyte measurements as well as devices, apparatuses and systems incorporating the same |
WO2014140172A1 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same |
EP3385706A1 (en) | 2013-03-15 | 2018-10-10 | Roche Diabetes Care GmbH | Methods of scaling data used to construct biosensor algorithms as well as devices, apparatuses and systems incorporating the same |
WO2014140177A2 (en) | 2013-03-15 | 2014-09-18 | Roche Diagnostics Gmbh | Methods of detecting high antioxidant levels during electrochemical measurements and failsafing an analyte concentration therefrom as well as devices, apparatuses and systems incorporting the same |
US9863811B2 (en) | 2014-08-15 | 2018-01-09 | Scanadu Incorporated | Precision luxmeter methods for digital cameras to quantify colors in uncontrolled lighting environments |
US10451577B2 (en) | 2016-03-16 | 2019-10-22 | Arkray, Inc. | Substance measuring method and measuring apparatus using electrochemical biosensor |
US11230727B2 (en) | 2016-10-05 | 2022-01-25 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
US12024735B2 (en) | 2016-10-05 | 2024-07-02 | Roche Diabetes Care, Inc. | Detection reagents and electrode arrangements for multi-analyte diagnostic test elements, as well as methods of using the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE36268E (en) | Method and apparatus for amperometric diagnostic analysis | |
US5108564A (en) | Method and apparatus for amperometric diagnostic analysis | |
US5128015A (en) | Method and apparatus for amperometric diagnostic analysis | |
US6153069A (en) | Apparatus for amperometric Diagnostic analysis | |
CA2224308C (en) | Electrochemical biosensor test strip | |
EP0636879B1 (en) | Method for producing a biosensor | |
US6855243B2 (en) | Electrochemical test strip having a plurality of reaction chambers and methods for using the same | |
EP0710358B1 (en) | Potentiometric biosensor and the method of its use | |
US6767441B1 (en) | Biosensor with peroxidase enzyme | |
Hilditch et al. | Disposable electrochemical biosensors | |
US6214612B1 (en) | Cholesterol sensor containing electrodes, cholesterol dehydrogenase, nicotinamide adenine dinucleotide and oxidized electron mediator | |
KR20030036609A (en) | Hemoglobin sensor | |
US5876952A (en) | Non-invasive glucose biosensor: determination of glucose in urine | |
AU644059B2 (en) | Method and apparatus for amperometric diagnostic analysis | |
CA1340516C (en) | Method and apparatus for amperometric diagnostic analysis | |
JP2543057B2 (en) | Biosensor manufacturing method and biosensor electrode plate manufacturing method | |
IL153582A (en) | Hemoglobin sensor | |
MXPA97010374A (en) | Electroquim biosensor test strip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ROCHE DIAGNOSTICS CORPORATION, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOEHRINGER MANNHEIM CORPORATION;REEL/FRAME:009730/0414 Effective date: 19981211 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC.,INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS CORPORATION;REEL/FRAME:015215/0061 Effective date: 20040101 Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS CORPORATION;REEL/FRAME:015215/0061 Effective date: 20040101 |
|
AS | Assignment |
Owner name: CORANGE INTERNATIONAL LIMITED (UNDIVIDED 1/2 INTER Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS OPERATIONS, INC.;REEL/FRAME:015756/0677 Effective date: 20040423 |
|
AS | Assignment |
Owner name: ROCHE OPERATIONS LTD.,BERMUDA Free format text: CHANGE OF NAME;ASSIGNOR:CORANGE INTERNATIONAL LIMITED;REEL/FRAME:022634/0371 Effective date: 20080715 Owner name: ROCHE OPERATIONS LTD., BERMUDA Free format text: CHANGE OF NAME;ASSIGNOR:CORANGE INTERNATIONAL LIMITED;REEL/FRAME:022634/0371 Effective date: 20080715 |
|
AS | Assignment |
Owner name: BOEHRINGER MANNHEIM CORPORATION,INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TALL OAK VENTURES;REEL/FRAME:023892/0975 Effective date: 19921013 |
|
AS | Assignment |
Owner name: ROCHE DIABETES CARE, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS OPERATIONS, INC.;REEL/FRAME:036008/0670 Effective date: 20150302 |
|
AS | Assignment |
Owner name: ROCHE DIABETES CARE, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE OPERATIONS LTD.;REEL/FRAME:067204/0694 Effective date: 20201215 |